SAN FRANCISCO / Jun 17, 2025 / Business Wire / Hinge Health, Inc. (NYSE:HNGE), today announced the launch of HingeSelect, a high-performance provider network for musculoskeletal (MSK) care. Hinge Health’s technology and in-house orthopedic physicians triage and direct downstream care, prioritizing the most appropriate evidence-based treatment. When in-person care, such as imaging or injections is required, members are seamlessly connected to pre-vetted providers at up to 50% below PPO rates. Combined with Hinge Health’s AI-powered digital exercise therapy, HingeSelect provides members with end-to-end MSK care while reducing costs for employers and health plans.
“We are moving towards a future where healthcare delivery itself will be automated via software and connected hardware - but many aspects of care still require in-person providers,” said Daniel Perez, Co-founder/CEO of Hinge Health. “HingeSelect creates a unified care experience. Any care that cannot yet be delivered by our technology, can now be directed to high-quality in-person providers - guaranteeing consistent, evidence-based support every step of the way.”
MSK conditions continue to rank as a top-two spend category for most employers.1 Orthopedic appointment wait times average 20 days2, and adherence to evidence-based care can vary significantly among providers.3 Finally, even when care is appropriate, inflated unit costs continue to drive up expenses for employers and members alike.4
Hinge Health is integrating its innovative digital platform with HingeSelect’s high-performance provider network, offering:
“HingeSelect is designed to be complementary to our health plan partners’ existing care models,” said Jim Pursley, President of Hinge Health. “By collaborating with health plans, we’re building an end-to-end MSK care journey that unifies care across digital and in-person for our shared members.”
About Hinge Health
Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California.
Forward-Looking Statements
This press release may contain forward-looking statements that involve risks and uncertainties, including, without limitation, certain statements regarding the launch, adoption, performance, or potential benefits of HingeSelect. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of management and information currently available to them. Forward-looking statements are subject to numerous known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those projected. More details about these and other risks that may impact our business are described in our filings with the U.S. Securities and Exchange Commission. We undertake no obligation to update these forward-looking statements, which speak only as of the date hereof.
1 Business Group on Health, 2025 Employer Health Care Strategy Survey
2 ECG Management Consultants, The Waiting Game: New Patient Appointment Access for US Physicians Whitepaper, 2024
3 SPINE, The Effect of Required Physiatrist Consultation on Surgery Rates for Back Pain, 2013
4 KFF, How Much More Than Medicare Do Private Insurers Pay? A Review of the Literature, 2020
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load